Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBefore and after pictures of Wegovy results circulate widely online, and they raise a reasonable question: do they reflect what most people actually experience? Clinical trials involving thousands of adults give us a more reliable picture than any single photo. The STEP 1 trial, published in the New England Journal of Medicine, found that adults taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks. That is a population average across participants with varying starting weights, activity levels and health histories — which is precisely why it is more useful than a curated photo. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The clearest evidence we have comes from the STEP programme, the clinical-trial series that supported Wegovy's approval. STEP 1, which enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition, reported average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. Roughly a third of participants lost 20% or more of their starting weight. Those are meaningful numbers, and they come with important context: participants followed a reduced-calorie diet and increased physical activity alongside the injection.
Semaglutide reviews that circulate as before and after pictures online tend to show people at the upper end of that distribution. A photo of someone who lost 25kg in a year is genuine, but it does not represent the person who lost 8kg at a lower dose, or who struggled with nausea and had to stay at 1mg longer than planned. The trial average is the honest benchmark. You can read a detailed look at how results change across timeframes on our Wegovy reviews page.
The newer 7.2mg dose of semaglutide (approved by the MHRA in April 2026) showed around 20.7% average weight loss over 72 weeks in trial data, narrowing the gap with tirzepatide at higher doses. That figure will start appearing in before and after content online, so it is worth knowing which dose a photo relates to.
Semaglutide before and after pictures carry almost no clinical information. They rarely specify the dose, how long the person was on treatment, whether they had dose reductions for side effects, or what their diet and activity looked like. They also go through a social-media filter: people who had unremarkable results are far less likely to post.
Starting weight matters a lot here. Someone starting at 130kg and losing 15% loses nearly 20kg. Someone starting at 85kg loses about 13kg. Both results are clinically significant. Both look very different in a photograph. A before and after picture with no starting weight, no timeframe and no dose label is essentially decorative.
A more practical question than "what does a Wegovy transformation look like?" is how long the process typically takes. Our page on how long Wegovy takes to work covers the titration timeline honestly, including why the first few months often produce modest visible change while the dose is still building.
Wegovy begins at 0.25mg and increases in roughly four-weekly steps: 0.25mg, 0.5mg, 1.0mg, 1.7mg, then 2.4mg as the maintenance dose. Some people remain below the maintenance dose for several months, either because their prescriber judges it appropriate or because side effects make faster escalation uncomfortable.
That means a one-month Wegovy before and after (however compelling it looks online) is taken during the 0.5mg or 1.0mg phase, not at the therapeutic maintenance dose. Weight change at that stage is real but modest for most people. Our one-month Wegovy results page sets realistic expectations for that window specifically.
The pen lives in the fridge between doses, so the weekly routine is consistent: injection day, back in the fridge door, same day each week. That regularity matters because consistency of dosing is part of what the trial results reflect. Missing doses or repeatedly shifting injection day can affect how the medicine works. The guidance on how long to stay on Wegovy is relevant here too, stopping early is one of the most common reasons results fall short of what clinical trials suggest is possible.
The most honest advice is to treat trial averages as your guide and before and after photos as anecdote. An average of 15% body-weight reduction over 68 weeks is clinically meaningful, for many people it is associated with real improvements in blood pressure, cholesterol and blood-sugar control, not just a change in clothes size. NICE's recommendation of semaglutide for weight management was based on that evidence, not on social-media transformations.
Your starting position, the dose you reach, and how long you stay on treatment will shape your result more than any photo suggests. The before and after pictures page on this site unpacks those variables in detail. And if you want a comparison across the titration journey, the three-month mark is where most people begin to see more consistent change.
Wegovy is a prescription-only medicine. If you are considering it, the practical starting point is a clinical assessment, not a photograph. Our prescribers review every consultation personally on the same day it is submitted. If you would like to understand whether treatment is appropriate for your situation, you can find out more about the weight-loss treatments we offer or go straight to a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.